Citations

Clear

5212 citation(s) found for "Wang, Li-Ju".

Modulation of TRIM72 Alters the Repair Capacity of Lung Epithelial Cells
Kim, Seong Chul, Kellett, Thomas, Nishi, Miyuki , Zhou, Beiyun , Flodby, Per , Takeshima, Hiroshi , Hubmayr, Rolf D., Zhao, Xiaoli , Wang, Shaohua , Nagre, Nagaraja N. , Shilo, Konstantin , Ghadiali, Samir N.

Mayo Clinic

Annals of the American Thoracic Society | April 2, 2015 | Volume: 12 | Issue: Supplement_1 | Pages: S72-S72

10.1513/annalsats.201406-277mg Get It

Molecular characterization of epithelioid haemangioendotheliomas identifies novel WWTR1–CAMTA1 fusion variants
Patel, Nimesh R, Salim, Alaa A. , Sayeed, Hadi, Sarabia, Stephen F. , Hollingsworth, Faith, Warren, Mikako , Jakacky, Jared, Tanas, Munir R. , Oliveira, André M. , Lazar, Alexander J. , López‐Terrada, Dolores , Wang, Wei‐Lien , Patel, Nimesh R. , Patel, Nimesh R, Rubin, Brian P. , Lazar, Alexander J

Mayo Clinic

Histopathology | March 27, 2015 | Volume: 67 | Issue: 5 | Pages: 699-708

10.1111/his.12697 | PMID 25817592 Get It

AimsEpithelioid haemangioendothelioma (EHE) is a malignant vascular neoplasm. Subsets have been characterized previously by translocations resulting in either WWTR1–CAMTA1 or YAP1–TFE3 fusion. We sought to develop molecular and immunohistochemical (IHC) assays to aid in the diagnosis and characterization of EHE.Methods and resultsFifty‐two formalin‐fixed, paraffin‐embedded (FFPE) cases diagnosed between 2002 and 2014 were retrieved from the pathology files of our institutions. Reverse transcription–polymerase chain reaction (RT–PCR) assays were optimized to detect WWTR1–CAMTA1 and YAP1–TFE3 fusion transcripts in FFPE tissue and transcription factor E3 (TFE3) protein accumulation was examined by immunohistochemistry (IHC). RNA was extracted from 33 adequate samples, with more recent cases providing a greater yield of high quality RNA. Fourteen of 18 informative cases were positive for WWTR1–CAMTA1 fusion transcripts, four of which showed higher‐grade cytological features termed by some as ‘malignant EHE’. Novel in‐frame fusion transcripts were identified in four cases by direct sequencing. IHC revealed variable nuclear TFE3 staining in six of 17 cases; three with patchy staining showed WWTR1–CAMTA1 fusion. One of 18 informative cases was positive for YAP1–TFE3 fusion and showed strong nuclear TFE3 staining by IHC.ConclusionsThis study confirms the high incidence of WWTR1–CAMTA1 and YAP1–TFE3 rearrangements in EHE and indicates that the staining pattern for TFE3 IHC is critical for specificity.
Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci
Coetzee, Simon G. , Shen, Howard C., Hazelett, Dennis J. , Lawrenson, Kate , Kuchenbaecker, Karoline , Rhie, Suhn K. , Levanon, Keren , Karst, Alison M., Drapkin, Ronny , Ramus, Susan J. , Offit, Kenneth, Chenevix‐Trench, Georgia , Monteiro, Álvaro N.A. , Antoniou, Antonis C. , Freedman, Matthew L., Coetzee, Gerhard A. , Gayther, Simon A. , Antonenkova, Natalia, Bean, Yukie T., Beckmann, Matthias W. , Bisogna, Maria, Bogdanova, Natalia , Brinton, Louise A. , Bruinsma, Fiona , Chang‐Claude, Jenny, Chen, Ann , Chen, Zhihua , Cunningham, Julie M. , Dansonka‐Mieszkowska, Agnieszka , Dicks, Ed , Dörk, Thilo , Eccles, Diana , Easton, Douglas F. , Edwards, Robert P., Eilber, Ursula, Ekici, Arif B. , Fasching, Peter A. , Gao, Yu‐Tang , Giles, Graham G. , Glasspool, Rosalind , Goode, Ellen L. , Grownwald, Jacek, Harrington, Patricia, Harter, Philipp , Hasmad, Hanis Nazihah, Hein, Alexander , Heitz, Florian , Hildebrandt, Michelle A.T., Hillemanns, Peter , Høgdall, Claus , Hosono, Satoyo , Iversen, Edwin S., Jakubowska, Anna , James, Paul A. , Jensen, Allan , Ji, Bu‐Tian , Kjær, Susanne K. , Kelemen, Linda E. , Kellar, Melissa, Kelley, Joseph L., Kiemeney, Lambertus A. , Krakstad, Camilla , Kupryjańczyk, Jolanta , Lambrechts, Diether , Lambrechts, Sandrina, Le, Nhu D. , Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A. , Lissowska, Jolanta , Lu, Karen, Lubiński, Jan , Lundvall, Lene, Massuger, Leon F.A.G. , Matsuo, Keitaro , McGuire, Valerie , McLaughlin, John R., McNeish, Ian, Menon, Usha , Moysich, Kirsten B., Narod, Steven A., Nedergaard, Lotte , Ness, Roberta B., Azmi, Mat Adenan Noor, Odunsi, Kunle , Oršulić, Sandra , Pearce, Celeste Leigh, Pelttari, Liisa M. , Permuth‐Wey, Jennifer, Phelan, Catherine M., Pike, Malcolm C., Rossing, Mary Anne, Rothstein, Joseph H. , Runnebaum, Ingo B., Rzepecka, Iwona K. , Salvesen, Helga B., Schildkraut, Joellen M. , Schwaab, Ira, Sellers, Thomas A. , Shu, Xiao‐Ou, Shvetsov, Yurii B. , Sieh, Weiva , Song, Honglin , Southey, Melissa C. , Sucheston, Lara, Tangen, Ingvild L. , Teo, Soo‐Hwang , Thompson, Pamela J., Timorek, Agnieszka, Tworoger, Shelley S. , Altena, Anne M. van , Nieuwenhuysen, Els Van , Vergote, Ignace , Vierkant, Robert A. , Wang‐Gohrke, Shan , Walsh, Christine , Wentzensen, Nicolas, Whittemore, Alice S. , Wicklund, Kristine G. , Woo, Yin Ling , Wu, Xifeng , Wu, Anna H. , Lu, Karen H. , McNeish, Iain A. , Lambrechts, Diether , Tyrer, Jonathan P. , Couch, Fergus J. , Pharoah, Paul D.P. , Noushmehr, Houtan , Anton‐Culver, Hoda , Baker, Helen H. , Bandera, Elisa V. , Berchuck, Andrew , Bjørge, Line , Brooks‐Wilson, Angela , Bützow, Ralf C. , Campbell, Ian , Carty, Karen , Cook, Linda S. , Cramer, Daniel W. , Cybulski, Cezary , Dennis, Joe , Doherty, Jennifer A. , Bois, Andreas du , Dürst, Matthias , Fridley, Brooke L. , Gentry‐Maharaj, Aleksandra , Goodman, Marc T. , Hildebrandt, Michelle A.T. , Høgdall, Estrid , Karlan, Beth Y. , Lester, Jenny, Liang, Dong , Lu, Karen, McLaughlin, John R., McNeish, Ian, Modugno, Francesmary , Olson, Sara H. , Orlow, Irene , Weber, Rachel Palmieri , Pejovic, Tanja B. , Poole, Elizabeth M. , Risch, Harvey A. , Rosen, Barry P. , Rudolph, Anja , Siddiqui, Nadeem , Terry, Kathryn L. , Wentzensen, Nicolas , Wilkens, Lynne R. , Yang, Hannah , Zheng, Wei , Ziogas, Argyrios , Pelttari, L M , Dörk, Thilo , Lambrechts, Diether , Giles, Graham G , James, Paul , Kiemeney, Lambertus A , Kjaer, Susanne K , McNeish, Iain A , Ramus, Susan J , Teo, Soo H , Tworoger, Shelley S , Hein, Alexander , Hillemanns, Peter , Jensen, Allan , Vierkant, Robert A , Eccles, Diana , Menon, Usha , Lawrenson, Kate , Hazelett, Dennis J , Coetzee, Simon G , Monteiro, Alvaro N , Lissowska, Jolanta , Southey, Melissa C , Glasspool, Rosalind , Matsuo, Keitaro , Heitz, Florian , Jakubowska, Anna , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Ekici, Arif B , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Drapkin, Ronny , Høgdall, Claus K , Lubinski, Jan

Mayo Clinic

Human Molecular Genetics | March 24, 2015 | Volume: 24 | Issue: 13 | Pages: 3595-3607

10.1093/hmg/ddv101 | PMID 25804953 Get It

Molecularly Engineered Biodegradable Polymer Networks with a Wide Range of Stiffness for Bone and Peripheral Nerve Regeneration
Wang, Shanfeng , Ruiter, Godard C. W. de , Spinner, Robert J. , Windebank, Anthony J. , Yaszemski, Michael J. , Lu, Lichun , Kempen, Diederik H.R. , Cai, Lei

Mayo Clinic

Advanced Functional Materials | March 24, 2015 | Volume: 25 | Issue: 18 | Pages: 2715-2724

10.1002/adfm.201500105 Get It

To satisfy different mechanical requirements in hard and soft tissue replacements, a series of biodegradable and crosslinkable copolymers of poly(propylene fumarate)‐co‐polycaprolactone (PPF‐co‐PCL) are synthesized and employed to fabricate 2D disks and 3D scaffolds via photocrosslinking. Thermal properties such as the glass transition temperature (Tg) and melting temperature (Tm) of the PPF‐co‐PCL networks can be controlled efficiently by varying the PCL composition (φPCL). As a result, their mechanical properties vary significantly from hard and stiff materials to soft and flexible ones with increasing φPCL, making them attractive candidate materials for bone and peripheral nerve regeneration, respectively. Several PPF‐co‐PCL formulations are selected to perform in vitro cell studies using mouse pre‐osteoblastic MC3T3‐E1, rat Schwann cell precursor line (SPL201), and pheochromocytoma (PC12) cells, and in vivo animal testing in the rat femur bone defect model and in the rat sciatic nerve transection model. The formation of new bone in the porous bone scaffolds with a low φPCL and guided axon growth through the nerve conduits with a higher φPCL suggest that crosslinked PPF‐co‐PCLs have appropriate compatibility and functionality. Furthermore, the role of surface stiffness in modulating cellular behavior and functions is verified on the crosslinked PPF‐co‐PCL surfaces without any pretreatments.
An international randomised trial of celecoxib versus celecoxib plus difluoromethylornithine in patients with familial adenomatous polyposis
Lynch, Patrick M, Burke, Carol A. , Phillips, Robin, Morris, Jeffrey S. , Slack, Rebecca, Wang, Xuemei , Liu, Jun , Patterson, Sherri, Rodrı́guez-Bigas, Miguel A. , Half, Elizabeth , Bülow, Steffen, Latchford, Andrew , Clark, Sue, Ross, William A., Malone, Bonnie, Hasson, Hennie, Hawk, Ernest T. , Lynch, Patrick M, Sinicrope, Frank A. , Richmond, Ellen S. , Burke, Carol A

Mayo Clinic

Gut | March 20, 2015 | Volume: 65 | Issue: 2 | Pages: 286-295

10.1136/gutjnl-2014-307235 | PMID 25792707 Get It

Background and aim Although Non-steroidal anti-inflammatory drugs reduce colorectal adenoma burden in familial adenomatous polyposis (FAP), the utility of combining chemopreventive agents in FAP is not known. We conducted a randomised trial of celecoxib (CXB) versus CXB+diflouromethylornithine (DFMO) to determine the synergistic effect, if any. Methods The primary endpoint was % change in adenoma count in a defined field. Secondary endpoints were adenoma burden (weighted by adenoma diameter) and video review of entire colon/rectal segments. Adverse event (AEs) were monitored by National Cancer Institution toxicity criteria. Results 112 subjects were randomised: 60 men and 52 women at a mean age of 38 years. For the 89 patients who had landmark-matched polyp counts available at baseline and 6 months, the mean % change in adenoma count over the 6 months of trial was −13.0% for CXB+DFMO and −1.0% for CXB (p=0.69). Mean % change in adenoma burden was −40% (CXB+DFMO) vs −27% (CXB) (p=0.13). Video-based global polyp change was −0.80 for CXB+DFMO vs −0.33 for CXB (p=0.03). Fatigue was the only significant AE, worse on the CXB arm (p=0.02). Conclusions CXB combined with DFMO yielded moderate synergy according to a video-based global assessment. No significant difference in adenoma count, the primary endpoint, was seen between the two study arms. No evidence of DFMO-related ototoxicity was seen. There were no adverse cardiovascular outcomes in either trial arm and no significant increase in AEs in the CXB+DFMO arm of the trial. Differences in outcomes between primary and secondary endpoints may relate to sensitivity of the endpoint measures themselves. Trial registration number ClinicalTrials.gov number N01-CN95040.
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Komrokji, Rami S. , Seymour, John F. , Roberts, Andrew W. , Wadleigh, Martha , To, Luen Bik, Scherber, Robyn M. , Turba, E , Dorr, Andrew, Zhu, Joy, Wang, Lixia , Granston, Tanya, Campbell, Mary S., Scherber, Robyn, Mesa, Ruben A. , Roberts, Andrew W , Komrokji, Rami S

Mayo Clinic

Blood | March 11, 2015 | Volume: 125 | Issue: 17 | Pages: 2649-2655

10.1182/blood-2013-02-484832 | PMID 25762180 Get It

Key Points Pacritinib reduced myelofibrosis-related splenomegaly and patient symptoms without causing clinically significant myelosuppression. Pacritinib had activity and was well tolerated in patients with preexisting anemia and thrombocytopenia.
Shared Decision Making and Use of Decision Aids for Localized Prostate Cancer
Wang, Elyn H. , Gross, Cary P. , Tilburt, Jon C. , Yu, James B. , Nguyen, Paul L. , Smaldone, Marc C., Shah, Nilay D. , Abouassally, Robert, Sun, Maxine , Kim, Simon P. , Yu, James B

Mayo Clinic

JAMA Internal Medicine | March 9, 2015 | Volume: 175 | Issue: 5 | Pages: 792

10.1001/jamainternmed.2015.63 | PMID 25751604 Get It

Targeting the Spleen Tyrosine Kinase with Fostamatinib as a Strategy against Waldenström Macroglobulinemia
Kuiatse, Isere, Lin, Heather , Bjorklund, Chad C. , Weber, Donna M., Wang, Michael , Shah, Jatin J., Jones, Richard J., Ansell, Stephen M. , Orlowski, Robert Z. , Baladandayuthapani, Veerabhadran , Thomas, Sheeba K. , Zhang, Xing‐Ding , Yang, Guang , Treon, Steven P. , Orlowski, Robert Z.

Mayo Clinic

Clinical Cancer Research | March 6, 2015 | Volume: 21 | Issue: 11 | Pages: 2538-2545

10.1158/1078-0432.ccr-14-1462 | PMID 25748087 Get It

Abstract Purpose: Waldenström macroglobulinemia (WMG) is a lymphoproliferative disorder characterized by good initial responses to standard therapeutics, but only a minority of patients achieve complete remissions, and most inevitably relapse, indicating a need for novel agents. B-cell receptor signaling has been linked to clonal evolution in WMG, and Spleen tyrosine kinase (Syk) is overexpressed in primary cells, suggesting that it could be a novel and rational target. Experimental Design: We studied the impact of the Syk inhibitor fostamatinib on BCWM.1 and MWCL-1 WMG-derived cell lines both in vitro and in vivo, as well as on primary patient cells. Results: In WMG-derived cell lines, fostamatinib induced a time- and dose-dependent reduction in viability, associated with activation of apoptosis. At the molecular level, fostamatinib reduced activation of Syk and Bruton's tyrosine kinase, and also downstream signaling through MAPK kinase (MEK), p44/42 MAPK, and protein kinase B/Akt. As a single agent, fostamatinib induced tumor growth delay in an in vivo model of WMG, and reduced viability of primary WMG cells, along with inhibition of p44/42 MAPK signaling. Finally, fostamatinib in combination with other agents, including dexamethasone, bortezomib, and rituximab, showed enhanced activity. Conclusions: Taken together, these data support the translation of approaches targeting Syk with fostamatinib to the clinic for patients with relapsed and possibly even newly diagnosed WMG. Clin Cancer Res; 21(11); 2538–45. ©2015 AACR.
In Vitro Human Cell Line Models to Predict Clinical Response to Anticancer Drugs
Niu, Nifang, Wang, Liewei

Mayo Clinic

Pharmacogenomics | February 25, 2015 | Volume: 16 | Issue: 3 | Pages: 273-285

10.2217/pgs.14.170 | PMID 25712190 Get It

Trends in the Proportion of Patients With Lung Cancer Meeting Screening Criteria
Wang, Yi , Midthun, David E. , Wampfler, Jason A. , Deng, Bo , Stoddard, Shawn M., Zhang, Shuo , Zhang, Shuo , Yang, Ping

Mayo Clinic

JAMA | February 24, 2015 | Volume: 313 | Issue: 8 | Pages: 853

10.1001/jama.2015.413 | PMID 25710663 Get It